Ancrod (Arvin) on slow intravenous administration converts fibrinogen into fitbrin at a rate which does not cause intravascular thrombosis. The fibrin is eliminated from the oirculaition and the blood is thus rendered inooagulable. To test the efficacy of ancrod in the prevention of thrombosis after prosthetic replacement of the heart valves, the tricuspid valve was replaced with a polypropylene mitral valve in 17 calves, using cardiopulmonary bypass. with the controls which they had already established. In 17 calves the tricuspid valve was replaced with a polypropylene mitral valve using cardiopulmonary bypass. Three calves did not survive the operation and two others died in the postoperative period. One calf was not tested and was used as a control. Eleven calves were treated with ancrod over periods of 36 hours to 29 days.
Ancrod (Arvin) on slow intravenous administration converts fibrinogen into fitbrin at a rate which does not cause intravascular thrombosis. The fibrin is eliminated from the oirculaition and the blood is thus rendered inooagulable. To test the efficacy of ancrod in the prevention of thrombosis after prosthetic replacement of the heart valves, the tricuspid valve was replaced with a polypropylene mitral valve in 17 calves, using cardiopulmonary bypass. Five calves were eliminated from the study. Eleven calves were treated with ancrod, and one untreated calf was used as a control. Four out of five prosthetic valves in calves treated with ancrod for up to 72 hours were free of thrombus formation, and one out of three at one week. In the long-term study, fibrinogen titres rose after varying intervals, in spite of continual treatment with ancrod. This 'escape' of fibrinogen titres from the control of ancrod may be due to species resistance or to the development of immunity. Further study is in progress to elucidate this point and to gain further knowledge for the clinical application of ancrod.
Ancrod (Arvin) is a proteolytic enzyme derived from the venom of the Malayan pit viper (Agkistrodon rhodostoma with the controls which they had already established. In 17 calves the tricuspid valve was replaced with a polypropylene mitral valve using cardiopulmonary bypass. Three calves did not survive the operation and two others died in the postoperative period. One calf was not tested and was used as a control. Eleven calves were treated with ancrod over periods of 36 hours to 29 days.
TECHNIQUE
Young Hereford bull-calves were reared until they could eat and drink a normal diet by themselves before the operation. The average age at operation was 7 weeks and the average weight was 49-2 kg.
Administration of antibiotics, penicillin 1,000,000 units and streptomycin 0 5 g., by intramuscular injection twice a day was started 48 hours before the operation. A right thoracotomy was performed with the calf in the left lateral position. The chest was entered through the bed of the fifth rib. The right atrium was exposed by incising the peiicardium longitudinally, anterior to the right phrenic nerve.
Heparin, 3,000 units/kg. of body weight, was administered intravenously. The two cavae were cannulated through separate incisions in the right atrium. The aorta was cannulated for return of the oxygenated blood. These cannulae were connected to the appropriate limbs of the heart-lung circuit for the cardiopulmonary bypass. The perfusion was started. Hypothermia was not used, nor was the heart fibrillated.
The right atrium was opened during complete cardiopulmonary bypass. The tricuspid valve was excised and a sterilized polypropylene mitral prosthesis was inserted with 2/0 mersilene interrupted sutures. The maximum flow outlet of the prosthetic valve was directed towards the outflow tract of the right ventricle. The atrial incision was closed. The cardiopulmonary bypass was discontinued. The heart was decannulated when the cardiac function was sustained satisfactorily. The pericardium was then closed loosely with interrupted sutures. Protamine sulphate, 6-0 mg. /kg. of body weight, was administered intravenously. Two intercostal drains were inserted and connected to a chest drainage set. Haemostasis was secured and the chest was closed in layers. Any oozing points in the edges of the skin were carefully secured.
The internal jugular vein was cannulated for administration of ancrod and withdrawal of blood samples with a vinyl catheter, 25-0 cm. in length and 2-0 mm. in diameter.
Anaesthesia was discontinued and the calf was gradually allowed to breathe spontaneously. On one occasion (in calf 56) the infusion pump failed to deliver the full dose of ancrod, and the control of fibrinogen level was lost.
END OF EXPERIMENT
Except in the control experiment, or when the calf died of some other cause, the experiment was terminated by intravenous administration of 0*5-10 g. of thiopentone sodium in 10 ml. of normal saline. Heparin, 10,000 i.u., was injected intravenously before the circulatory arrest to prevent post-mortem clot formation.
A complete post-mortem examination was made. The wounds were observed for healing and the thoracic cavity for evidence of haemorrhage. The prosthetic valve, all the chambers of the heart, and the pulmonary artery and its branches were examined for the presence of thrombus formation. Thrombus, when present, was examined microscopically, the preparations being stained with haematoxylin and eosin and van Gieson stains.
RESULTS
Neither wound disruption nor excessive haemorrhage was observed in any of the calves. Of the 17 calves operated upon, three did not survive the operation. Two calves died early in the postoperative period, one six hours after operation before ancrod treatment was begun and the other after eight hours, having received only the initial The experiments on the other two were terminated on the 27th and 29th day respectively. All these calves showed 'escape phenomenon' on the ancrod treatment. Thrombus had formed in concentric layers on the atrial and ventricular aspects of the valve ring but there was no thrombus within the valve. The thrombus was not propagated. Small emboli were detected in the peripheral lung fields of all the animals in this group. SURVIVAL FOR ONE WEEK Three calves (nos. 48, 52, and 53) were killed after one week of treatment with ancrod. In one calf (no. 48) there was only a thin pannus of platelet thrombus on both aspects of the valve ring. The valve orifice was free and the thrombus was not propagated.
In the other two calves, thrombus formation was more marked, but again there was no thrombus within the valve orifice nor was it propagated.
The excess of ancrod present in the blood samples interfered with the estimation of fibrinogen titres in the two later calves, and the results could not be correlated with the titres. (33%) at one week. When thrombus did form while the calves were treated with ancrod it was almost limited to the ring of the prosthetic valve. There was no thrombus in the atrium or ventricle. The orifice of the valve was free, and the thrombus was not propagated, whereas in the untreated (control) calf the mechanism of the valve was completely enmeshed in thrombus which was propagated into the right ventricle and the pulmonary artery.
Thrombus formation, in the long-term study, could be related to an 'escape phenomenon' and consequent rise in the fibrinogen titres despite continual treatment wilth ancrod. The 'escape phenomenon' might be due either to species resistance or to development of immunity, and merits further study. The presence of infection in the inguinal wound in one of the calves might have been a contributing factor by accelerating the formation of fibrinogen.
It was feared that uncontrollable haemorrhage might occur and wound healing might be slow, owing to the total defibrination with ancrod, in spite of maximum haemostasis having been achieved both inside the chest and in the wound. However, excessive haemorrhage or wound disruption did not occur after early administration of ancrod in the calves. This does not, however, rule out the possibility of a risk of haemorrhage in man because of the species differences. More knowledge will have to be gained before a clinical trial is carried out.
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